Lenalidomide and Paclitaxel in Prostate Cancer

Summary

The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of Revlimid® (lenalidomide) that can be given in combination with paclitaxel to patients with prostate cancer who have failed treatment with taxanes. The goal of the Phase II part of this clinical research study is to learn if lenalidomide and paclitaxel can help to control prostate cancer. The safety of this combination treatment will be studied in both phases of the study. UPDATE: Study was terminated early due to slow accrual as a Phase I dose escalation study, without progression to Phase II study portion.

Timeline

Start

2009-08

Primary completion

2015-12

Completion

2015-12

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated early due to slow accrual as Phase I dose escalation study.”

Drugs

Indications